Antimicrobial therapy of device-related infections often fails, despite the in vitro susceptibility of the infecting strain. Therefore, alternative laboratory-based in vitro tests are required to predict the outcome. Fleroxacin, ciprofloxacin, aztreonam, and co-trimoxazole were tested against Escherichia coli ATCC 25922 in vitro and in the tissue-cage animal model. The importance of early treatment was evaluated by starting the drugs either 30 min before or 4, 12, and 24 h after bacterial challenge. Results were compared with the in vitro drug efficacy against nongrowing and adherent Escherichia coil ATCC 25922. The alternative in vitro tests correlated highly with the outcome in the tissue-cage animal model. In the prophylaxis group (drug given 30 min before bacterial challenge), co-trimoxazole was less efficacious than the other three drugs (P < 0.001). In delayed treatment, ciprofloxacin showed the highest cure rate. It was also more potent than the other drugs against nongrowing and adherent E. coil ATCC 25922. The efficacies of aztreonam, fleroxacin, and ciprofloxacin dropped significantly (P < 0.01) when the time interval between bacterial challenge and the start of treatment was delayed to >4 h. These data emphasize (i) the need for proper timing of prophylaxis in patients undergoing implant surgery, and (ii) the possibility of successful treatment of established devicerelated infections with drugs which kill not only growing but also nongrowing and adherent bacteria.
Infections associated with prosthetic devices remain a major clinical problem (19) . Antimicrobial therapy usually fails to cure such infections, unless the device has been removed (4) . The high susceptibility of implants to pyogenic infections is due in part to impaired local host defense mechanisms (24, 25) . Bacterial persistence is mainly related to the resistance of surface-adherent microorganisms to phagocytosis and antimicrobial treatment (7, 10, 11, 21, 23) . The choice of a therapeutic antimicrobial agent is usually guided by the in vitro susceptibility of the anticipated (prophylaxis) or the isolated (treatment) microorganism to the drug (9) . Importantly, however, bacteria in devicerelated infections are likely to be in the stationary phase of growth (silent infection), against which beta-lactam antibiotics show a diminished activity (20) . Furthermore, adherence of bacteria alters their susceptibility to antimicrobial agents (7, 23) . Additionally, a delay of prophylaxis in implant surgery has been shown to increase the risk of infection (13) .
Having previously shown that staphylococcal device-related infections can be cured with rifampin (23) Animal model. We used a previously described foreignbody animal model (25) . In brief, four sterile polytetrafluoroethylene (Teflon) tubes (32 by 10 mm), perforated by 130 regularly spaced 1-mm-diameter holes (CIBA-GEIGY Ltd., Basel, Switzerland) were aseptically implanted into the flanks of albino guinea pigs (weight, 800 to 1,100 g). Experiments were started after complete healing of the wound, i.e., 3 Pharmacokinetics. Pharmacokinetic studies were performed in guinea pigs with uninfected tissue cages. Every drug was injected i.p. Peak levels in serum (cardiac puncture) were determined at 1 h after drug administration and in tissue-cage fluid at 1, 3, and 5 h after drug administration. Trough levels in tissue-cage fluids were measured 12 h after a single dose of the antimicrobial agent. The half-lives of fleroxacin and ciprofloxacin in serum were calculated from the elimination rate constant determined by linear regression analysis. Antibiotic levels were determined in antibiotic medium 1 (Difco Laboratories, Detroit, Mich.) by agar diffusion bioassays (6) . Bacillus subtilis (Difco 0453-36-0) was used as the test strain for ciprofloxacin and fleroxacin, and E. coli ATCC 25922 was used as the test strain for aztreonam. Standard curves were generated from pooled heat-inactivated guinea pig serum (final concentration, 50%).
Results were calculated by microcomputer-assisted exponential regression analysis (Hewlett-Packard HP41V). Co-trimoxazole was determined by high-pressure liquid chromatography assay, which was kindly performed by Hoffmann-La Roche & Co., Ltd.
io8. (16) . For susceptibility testing with co-trimoxazole, Enterococcus faecalis ATCC 29212 was simultaneously used as the control strain in MHB. MBCs were also determined with MHB with pooled, heat-inactivated, 10% guinea pig serum to screen for a low content of thymidine in guinea pig serum (12) . MBCs of co-trimoxazole determined with E. coli and E. faecalis did not change by adding 10% pooled guinea pig serum. MBCs were determined as described in the Manual of Clinical Microbiology (18) . The antibiotic concentration that reduced the original inoculum by .99.9% was read as the MBC.
MBCs were also determined with bacteria in the stationary phase of growth, as described recently (23) . Briefly, MHB was replaced by phosphate-buffered saline (PBS; pH 7.4). Overnight cultures of E. coli were centrifuged (2,000 x g, 10 min) and resuspended in PBS to the appropriate inoculum. With an inoculum of _105 CFU/ml, bacterial counts remained in the same range for up to 36 h. Experiments were performed in duplicate.
The influence of the E. coli inoculum size on the MICs was examined by performing the test with 105 to 107 CFU/ml. To minimize a possible influence of any other variables, the test procedure was performed with all drugs simultaneously, and the inocula were appropriately diluted from the same overnight culture.
Time-kill curves. Time-kill curves of bacteria in the logarithmic growth phase were performed for bacteria grown in MHB (18) . For time-kill curves of bacteria in the stationary confirming that most colonies gave a copy of themselves on the agar. The two other slides were transferred with the rack in Ca2E (50 mg/liter)-supplemented Trypticase soy broth containing antibiotics at a concentration corresponding to the twofold standard MBC. After another 24 h, they were processed as described above. Colonies of controls (adherent inoculum) and samples were counted after pressing them onto agar and expressed as the number of CFU per slide. Experiments were excluded if the adherent CFU of the controls were <102 or >103 CFU per slide, in order to have similar adherent inocula in each experiment. The test with four samples each was repeated at least three times. The kill rate (in percent) was calculated as follows: 100 -(CFU per slide on drug incubated slides/CFU per slide on control slides) x 100. For better comparison with the results of the time-kill curves, these values were converted into the loga-it rithm of killing as follows: 2 -[log (100 -%killing)]. t Statistics. The Fisher exact test with the Bonferroni ad-t justment, when appropriate, was used for examining proportions in the animal studies. If no P value is indicated, they difference was not significant. Variance component analysis was done for adherence results by using statistics software (SAS; SAS Institute Inc., Cary, N.C.).
RESULTS
Pharmacokinetics. In the pharmacokinetic studies (Tabl4 1), the peak levels corresponded to those suggested fox humans by the manufacturer. Tissue-cage fluid trough levels exceeded the MBCs of aztreonam, fleroxacin, and ciprofloxacin. The tissue-cage peak level of co-trimoxazole showed a ratio very similar to that of trimethoprim-sulfamethoxazole, as tested in vitro (1:18 versus 1:20, respectively). Based on this ratio, the trough level would also exceed the MBC of trimethoprim-sulfamethoxazole. The trough level of sulfamethoxazole was above the MIC (4.8 ,ug/ml), but was below the MBC (38 ,ug/ml) of sulfamethoxazole as a single agent. The half-lives of ciprofloxacin and fleroxacin were 1.5 and 1.8 h, respectively.
Animal model. Mean bacterial counts in tissue-cage fluid Table 2 summarizes the results of the prophylaxis of tissue-cage infections with a single dose of an antimicrobial agent. Co-trimoxazole was significantly less efficacious than the other three drugs were, whether they were tested early or late after prophylaxis. Several tissue-cage fluids became sterile >1 day after the single-dose prophylaxis. Table 3 shows the results of a 4-day antimicrobial treatment of tissue-cage infections, starting at different time intervals after bacterial inoculation. All agents, except cotrimoxazole, were similarly effective if treatment was started 4 h after bacterial inoculation. A delay to 12 h significantly lowered the cure rates by aztreonam, fleroxacin, and ciprofloxacin. At this interval, ciprofloxacin was significantly more efficacious than the other drugs tested. At the 24-h interval, ciprofloxacin still sterilized 44% of the tissue-cage fluids.
MBCs in the stationary and logarithmic phases of bacterial growth. The MBCs of fleroxacin, aztreonam, and co-trimoxazole for E. coli were 6 to 1,300 times higher when they were tested in the stationary growth phase than when they were tested in the logarithmic growth phase (Table 4 ). In contrast, ciprofloxacin killed growing and nongrowing E. coli equally well.
Inoculum effect observed with E. coli ATCC 25922. Bacterial counts in tissue-cage fluid of untreated animals rose from 7 x 10' (inoculum) to approximately 1 x 107 CFU/ml within 24 h (Fig. 1) . Therefore, MICs were also tested with inocula corresponding to these in vivo conditions (Table 5 ). Whereas the MICs of both quinolones remained in the susceptible range at 106 CFU/ml, the test strain was highly resistant to co-trimoxazole and aztreonam at this inoculum. At 107 CFU/ml, the MICs of the quinolones also increased to the resistant range.
Time-kill studies. All antimicrobial agents except ciprofloxacin were less active against stationary-phase bacteria ( Fig. 2 and 3) .
Drug efficacy on glass-adherent E. coli ATCC 25922. Adherent microorganisms are not killed as well as planktonic bacteria are (11, 23) . We therefore tested the efficacy of the drugs against glass-adherent E. coli ATCC 25922 (Table 6 ). Co-trimoxazole completely failed to kill adherent bacteria in any experiment. In contrast, ciprofloxacin eradicated all adherent bacteria in three of three tests. This clear cutoff was not observed with fleroxacin or aztreonam, which reduced adherent bacteria in a range of 0.7 to 3 log units in different experiments. However, these two drugs were also more effective than co-trimoxazole (P < 0.01).
DISCUSSION
The ratio of the serum drug level of an antimicrobial agent to the MIC or the local antibiotic level to the MBC has been shown to correlate with the outcome in experimental infections (1, 5, 8, 17, 22) . In a recently published study (14) , the in vitro susceptibility predicted the clinical outcome. We analyzed the efficacy of four antimicrobial agents on adherent, growing, and nongrowing E. coli ATCC 25922 in vitro and compared these results with prophylaxis and treatment studies using an animal model for device-related infections (24, 25) . Drug levels in tissue-cage fluid exceeded the MIC at any time during the treatment. Thus, a similar outcome could be expected. Surprisingly, the in vivo efficacy of the four antimicrobial agents differed widely.
In contrast, the described alternative in vitro tests highly correlated with the outcome in the animal model. The properties of the antimicrobial agent needed for the optimal outcome were different whether the drug was administered early or late after bacterial challenge.
In the prophylaxis group, the bacterial density in tissue cages was 7 x 104 CFU/ml; i.e., it was similar to that of the regular MIC test conditions. All drugs except co-trimoxazole were equally efficacious. The complete failure to prevent infection by co-trimoxazole was unlikely to be related to the thymidine content of interstitial fluid, since MICs were not influenced by adding 10% pooled, heat-inactivated guinea pig serum to MHB (data not shown). It also cannot be explained by the inability of co-trimoxazole to kill nongrowing bacteria, since aztreonam was prophylactically efficient, despite the same drawback. Furthermore, different betalactam antibiotics were shown to prevent infection in patients who underwent orthopedic surgery (13) . However, it is conceivable that even in patients treated prophylactically, some microorganisms adhered to the implant and therefore could escape killing by co-trimoxazole (Table 6) .
If short-term treatment was started 4 h after bacterial challenge, all drugs except co-trimoxazole were equally effective. Four hours after inoculation, bacteria grew exponentially (Fig. 1) , but their density was not yet higher than 3 x 105 CFU/ml. For these reasons, neither the inability to kill nongrowing bacteria nor the inoculum effect could be an explanation for the treatment failures. Therefore, the inability of co-trimoxazole to kill surface-adherent E. coli best explains its lack of efficacy in vivo. The crucial property of an antimicrobial agent in the prophylaxis and early treatment group was the ability to kill adherent bacteria.
If therapy was delayed to 12 h after bacterial challenge, the cure rate of aztreonam dropped from 84 to 8%. The considerable inoculum effect of aztreonam (Table 5) could be a trivial explanation for the failure of delayed treatment, suggesting a clinical significance of the inoculum effect (3). At 12 h after inoculation, bacterial counts in tissue-cage fluid were near the plateau. The low activity of aztreonam against nongrowing E. coli therefore offers another explanation for its poor efficacy in the delayed treatment of tissue-cage infections.
Ciprofloxacin had the best efficacy against high inocula and nongrowing and adherent E. coli ATCC 25922 and was also most successful in the delayed treatment study. The ability of ciprofloxacin to sterilize tissue-cage abscesses remained similar whether the treatment was started at 12 or 24 h after infection. This indicates that an antimicrobial agent with the described properties does not necessarily loose its activity if the start of the treatment is further delayed. The main reason for the treatment failure of ciprofloxacin in 56% of the inoculations can be explained by the short treatment course. Unfortunately, longer treatment courses cannot be tested, since guinea pigs do not tolerate prolonged antimicrobial therapy (2, 15) . In these late-treatment groups, the potency of an antimicrobial agent against nongrowing and adherent bacteria and high inocula also determined the outcome.
In conclusion, the outcome of antimicrobial therapy in this animal model depended on the potency of the drug against nongrowing and adherent bacteria and the timing of drug administration. Established infections require long-term treatment with such drugs for complete healing.
